US › Healthcare

Mesoblast Ltd (MESO)

US · Healthcare · Biotechnology

$14.87+3.19%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$34.5M

Revenue YoY

+390.7%

Net profit

$-8.7M

EPS

$0.00

EPS estimate

$-0.05

Net margin

-25.2%

EPS came in at 0.00 against a street estimate of -0.05 — a beat of 100.0%.

Key statistics

Market cap

$1.91B

Forward P/E

454.5

P/B

3.43

Book value

$4.38

EPS (TTM)

$-0.44

52-week high

$21.50

52-week low

$13.05

50-day MA

$16.13

200-day MA

$16.12

Beta

0.82

Analyst view

Analysts rate Mesoblast Ltd a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $37.00.

Shareholding

Insiders

5.81%

Institutions

3.27%

Largest institutional holders

Fund	Stake
BlackRock Inc	0.49%
Morgan Stanley - Brokerage Accounts	0.40%
The Goldman Sachs Group Inc	0.31%
Susquehanna International Group, LLP	0.30%
SRS Capital Advisors Inc	0.13%
UBS Group AG	0.10%
Bank of America Corp	0.08%
Jane Street Group LLC	0.08%

Corporate actions

Action	Detail	Date
Split	1 : 2 effective Jan 10, 2024	2024-01-10

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mesoblast Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.